Advertisement

Topics

Multi-year agreement signed focusing on immune tolerance

06:26 EDT 22 Aug 2017 | EPM Magazine

German biotechnology company, Topas Therapeutics, has signed a multi-year agreement with Eli Lilly and Company, which will see the companies collaborate to generate drug candidates in the field of antigen specific tolerance induction.

Original Article: Multi-year agreement signed focusing on immune tolerance

NEXT ARTICLE

More From BioPortfolio on "Multi-year agreement signed focusing on immune tolerance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...